The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Open accessAbstract
Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, which led to the limitation of clinical application. Motivated by potent and durable efficacy of ICIs, oncologists endeavor to explore the mechanisms of resistance to ICIs and increase the drug sensitivity. It is known that heterogeneity of gut microbiome in populations may result in different outcomes of therapy. In xenograft model, bacteria in gut have been proved as a crucial factor regulating immunotherapy efficacy. And the similar phenomenon was obtained in patients. In this review, we summarized relevant advancements about gut microbiome and ICIs. Furthermore, we focused on modulatory function of gut microbiome in ICIs therapy and possible antitumor mechanism of specific commensals in ICIs treatment. We propose that gut microbiome is an important predictive factor, and manipulation of gut microbiome is feasible to elevate response rate in ICIs therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some gut bacteria act as suppressors of inhibitory signal pathways, facilitate antigen presentation, and improve specific antitumor immunity (118).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [118]
In the citing paper
“In conclusion, in view of the metabolic function elicited by gut microbiota, we infer that their metabolic byproducts are perceived by cells and molecules of the immune system and modulate the equilibrium between pro- and antitumor functions.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [118]
In the citing paper
“The influence of gut microbiota on host immunity is multifaceted, simultaneously regulating the gut mucosal immune system and systemic immune system (Fig. 2d) [307–310].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [308]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 15×
“The fecal microbiome transplantation in mice supported the conclusions aforementioned [11].”
BackgroundMethodResultInfluential
Cited by
Sorted by citations
Items 101–179 of 179
Lin, A., Gu, T., Hu, X., Zhang, J., & Luo, P. (2022) · Journal of Immunology Research · doi:10.1155/2022/8179799 · Cited by 16
Cha, Y. J., Kim, E. Y., Choi, Y. J., Kim, C. Y., Park, M. K., & Chang, Y. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1154881 · Cited by 16
Sitthideatphaiboon, P., Somlaw, N., Zungsontiporn, N., Ouwongprayoon, P., Sukswai, N., Korphaisarn, K., Poungvarin, N., Aporntewan, C., Hirankarn, N., Vinayanuwattikun, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-79339-6 · Cited by 17
Seesaha, P. K., Chen, X., Wu, X., Xu, H., Li, C., Jheengut, Y., Zhao, F., Liu, L., & Zhang, D. (2020) · Future Oncology · doi:10.2217/fon-2019-0552 · Cited by 20
Self-citationAnalysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy
Li, Y., Wang, S., Lin, M., Hou, C., Li, C., & Li, G. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0927-0 · Cited by 15
Zhang, B., Tan, H., Kuang, J., Zhou, B., Liang, S., Pang, X. Y., Ouyang, Y., Zhang, Z., Long, Y., & Zhang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02487-4 · Cited by 15
Xing, X., Zhao, Q. C., Zhou, J., Zhou, R., Liu, Y., Qin, X., Zhang, M., Zhong, Y., Wang, J., Tian, M., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06084-1 · Cited by 14
The biology of combination immunotherapy in recurrent metastatic head and neck cancer
Yuan, X., Yi, M., Zhang, W., Xu, L., Chu, Q., Luo, S., & Wu, K. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106002 · Cited by 13
Self-citationLi, J., Jia, J., Teng, Y., Wang, X., Xia, X., Song, S., Zhu, B., & Xia, X. (2025) · Foods · doi:10.3390/foods14030387 · Cited by 14
Sharafi, F., Hasani, S. A., Alesaeidi, ., Kahrizi, M. S., Adili, A., Ghoreishizadeh, S., Shomali, N., Tamjidifar, R., Aslaminabad, R., & Akbari, M. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02682-z · Cited by 13
Wusiman, D., Guo, L., Li, L., Zhang, X., Zhao, X., An, Z., Huang, Z., Zhang, Y., Li, Z., Ying, J., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02126-z · Cited by 12
Dora, D., Weiss, G. J., Megyesfalvi, Z., Gállfy, G., Dulka, E., Kerpel-Fronius, A., Berta, J., Moldvay, J., Dome, B., & Lohinai, Z. (2023) · Cancers · doi:10.3390/cancers15205091 · Cited by 12
Therapeutic Modulation of the Microbiome in Oncology: Current Trends and Future Directions
Saraswat, I., & Goel, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010353600241109132441 · Cited by 12
Mógor, F., Kovács, T., Lohinai, Z., & Dóra, D. (2021) · Applied Sciences · doi:10.3390/app112412000 · Cited by 11
Shen, S., Wu, Q., Liu, J., Wu, L., Zhang, R., Uemura, Y., Yu, X., Chen, L., & Liu, T. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211056505 · Cited by 11
Chen, X., Wang, G., Qin, L., Hu, B., & Li, J. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08346-4 · Cited by 11
Chen, Y., & Lai, X. (2022) · Mathematical Biosciences · doi:10.1016/j.mbs.2022.108868 · Cited by 12
Wang, F., Chen, W., Jia, Y., He, T., Wu, S., Xiang, J., Chen, R., Jiang, Q., Yu, T., Lan, Y., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70994 · Cited by 13
“Right-to-Try” experimental drugs: an overview
Mahant, V. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02427-4 · Cited by 10
Gao, X., Peng, L., Zhang, L., Huang, K., Yi, C., Li, B., Meng, X., & Li, J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03848-4 · Cited by 9
Emerging Targets of Immunotherapy in Gynecologic Cancer
Cheng, H., Zong, L., Kong, Y., Gu, Y. L., Yang, J., & Xiang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s282530 · Cited by 10
Piazzesi, A., Pane, S., Russo, A., CHIERICO, F. D., Francalanci, P., Cotugno, N., Rossi, P., Locatelli, F., Palma, P., & Putignani, L. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1281440 · Cited by 9
Cai, Y., Zhao, F., & Cheng, X. (2025) · Biomolecules · doi:10.3390/biom15111546 · Cited by 10
[Therapeutic Relevance of Human Microbiota and Lung Cancer].
Zhou, H., Suo, J., & Zhu, J. (2019) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2019.07.09 · Cited by 9
Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy
Dai, Z., Fu, J., Peng, X., Tang, D., & Song, J. (2022) · Cancers · doi:10.3390/cancers14194796 · Cited by 8
Revolutionizing Skin Cancer Treatment: The Rise of PD-1/PDL-1 and CTLA-4 as Key Therapeutic Targets
Sharma, N., Mazumder, R., & Rai, P. (2024) · Current Drug Targets · doi:10.2174/0113894501320281240822052657 · Cited by 8
Yu, J., Yin, Y., Yu, Y., Cheng, M., Zhang, S., Jiang, S., & Dong, M. (2022) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2022.2145966 · Cited by 8
Kareer, R., Ahuja, S., Chaudhary, N., & Arora, R. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154266 · Cited by 8
Small Animals Gut Microbiome and Its Relationship with Cancer
Ferrarias, T. M., & Santos, A. A. F. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95780 · Cited by 7
Intratumoral microbiome and gastrointestinal cancers
Li, S., Li, Q., & Lu, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1047015 · Cited by 7
Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
Ma, J., Wei, Q., Cheng, X. M., Zhang, J., Zhang, Z., & Su, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1170591 · Cited by 9
Bhatt, A., Haslam, A., & Prasad, V. K. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04656-8 · Cited by 7
Chen, N., Xu, X., & Fan, Y. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231189420 · Cited by 8
Katsurayama, N., Ishihara, H., Ishiyama, R., Nemoto, Y., Ikeda, T., Mizoguchi, S., Nakayama, T., Fukuda, H., Yoshida, K., Iizuka, J., et al. (2024) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10354 · Cited by 6
Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review
Stella, G. M., Scialò, F., Bortolotto, C., Agustoni, F., Sanci, V., Saddi, J., Casali, L., Corsico, A. G., & Bianco, A. (2022) · Cancers · doi:10.3390/cancers14133131 · Cited by 6
Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update
Lu, J., Yu, J., Xu, T., Li, Y., Chen, S., Zhou, Q., & Wang, L. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.126 · Cited by 5
Reddy, N., Lau, K., Naman, J., Lu, K. L., McGillivary, E., Salmasi, A., Liss, M. A., & Stewart, T. F. (2026) · OncoImmunology · doi:10.1080/2162402x.2025.2611458 · Cited by 4
Xu, J., Tian, Y., Hu, D., Xi, Y., & Yang, L. (2024) · MedComm – Oncology · doi:10.1002/mog2.85 · Cited by 4
Una visión integral del cáncer (II). Campos de estudio y biomarcadores emergentes
Noguera, R., Burgos‐Panadero, R., Gamero‐Sandemetrio, E., de la Cruz‐Merino, L., & Naranjo, T. Á. (2019) · Revista Española de Patología · doi:10.1016/j.patol.2019.04.005 · Cited by 4
Saman, H. T., Saman, H. T., Shahab Uddin, M. S., Raza, S. S., Shrimali, R. K., & Rasul, K. I. (2020) · Clinical Oncology and Research · doi:10.31487/j.cor.2020.09.08 · Cited by 3
Arcila, M. E., Patel, U., Boroujeni, A. M., Yao, J., Chan, R., Chan, J., Rijo, I., Yu, W., Chaves, N., Patel, H., et al. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.06.002 · Cited by 3
Laboratory biomarkers of an effective antitumor immune response. Clinical significance.
Malkova, A. M., Sharoyko, V. V., Zhukova, N. V., Gubal, A. R., & Орлова, Р. В. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100489 · Cited by 5
Zuccaro, V., Lombardi, A., Asperges, E., Sacchi, P., Marone, P., Gazzola, A., Arcaini, L., & Bruno, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071748 · Cited by 3
Drymel, B., Tomela, K., Galus, Ł., Olejnik‐Schmidt, A., Mackiewicz, J., Kaczmarek, M., Mackiewicz, A. A., & SCHMIDT, M. T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168063 · Cited by 2
Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting
Santis, F. D., Vecchio, M. D., Castagnoli, L., de Braud, F., Cosimo, S. D., Franceschini, D., Fucà, G., Hiscott, J. B., Malmberg, K., McGranahan, N., et al. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.10.005 · Cited by 2
Low, J. L., Chong, W. Q., & Goh, B. C. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.01.003 · Cited by 2
Tisman, G. (2023) · Digital Medicine and Healthcare Technology · doi:10.5772/dmht.14 · Cited by 1
Anti-cancer alternative therapies: from inorganic nanoparticles to tumor-killing bacteria
Mihăescu, G., Constantin, M., Andronic, O., Bolocan, A., & Filip, R. (2022) · ROMANIAN BIOTECHNOLOGICAL LETTERS · doi:10.25083/rbl/27.2/3416.3421 · Cited by 1
Shatila, M., Cruz, C. C., Lu, L., Abdul-Baki, K., Baerman, E. A., Takigawa, K., Rivera, A. M., Lee, I. J.-A., Ngo, S., Sperling, G. L., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115405 · Cited by 1
Zhang, X., Ishikawa, D., & Nagahara, A. (2025) · International Immunology · doi:10.1093/intimm/dxaf038 · Cited by 3
Two stable gut microbiome guilds predict liver tumor class and treatment responses
Liu, Y., Zhang, Z., Wu, G. G., Li, B., Wang, L., Wang, J., Wei, Z., Wang, Z., Yang, J., Zhang, K., et al. (2026) · iMeta · doi:10.1002/imt2.70123 · Cited by 1
Sun, H., Pan, Z., Chen, Z., Teng, L., Jiang, Y., Chen, W., & Bi, L. (2026) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgag043 · Cited by 1
Targeting the cancer metabolism—immunity interface: update and perspectives
Carlo, E. D. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00776-2 · Cited by 1
Mice, Models, Microbiota: How Can We More Accurately Reflect Human Disease?
Ladak, R., & Philpott, D. J. (2021) · Journal of Undergraduate Life Sciences · doi:10.33137/juls.v15i1.36811 · Cited by 1
New potential checkpoint inhibitors in cancer therapy
Kopecký, J. (2022) · Onkologie · doi:10.36290/xon.2022.022 · Cited by 1
Healthy gut microbiome in the prevention of colorectal cancer
Rumman, M., Nagasaka, M., Al-Share, B. A., Azmi, A. S., & Uddin, M. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822238-6.00005-4 · Cited by 1
Physiological markers for immunotherapeutics: a review
Chowdhury, D., Das, A., Mishra, M., Khutere, T., & Bodakhe, S. H. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2443701 · Cited by 1
Doneparthi, P. S., Cao, H., Chen, W., Dou, W., Fang, H., & Smith, J. P. (2025) · Cancers · doi:10.3390/cancers17182998 · Cited by 1
Gut dysbiosis: not only with checkpoint inhibitors!
Piroth, M., Frénard, C., Quereux, G., Khammari, A., Corvec, S., & Dréno, B. (2019) · Clinical and Experimental Dermatology · doi:10.1111/ced.14018 · Cited by 1
Sharan, B., Chiliveru, S., Bagga, J., Kohli, S., Bharadwaj, A., Vaid, A. K., & Kumar, C. (2020) · Medicine · doi:10.1097/md.0000000000018889 · Cited by 1
Canine Genetics, Health and Medicine
Rutland, C. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.92513 · Cited by 1
Delivery, Feeding and Gender Differently Contribute to Infant Gut Microbiota DevelopmentPreprint
Ding, J., Ma, X., Ren, H., Zhi, C., Qi, X., Li, Z., Han, L., Zhao, X., Zhuo, Z., Li, A., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-828854/v1 · Cited by 1
Arora, R., Hermann, A., & Wargo, J. A. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_41-1
Human gut microbiota – its diversity and impact on our health
Wardak, S. (2021) · Medycyna Doświadczalna i Mikrobiologia · doi:10.32394/mdm.73.06
Arora, R., Hermann, A., & Wargo, J. A. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7147-9_41
Akhremchuk, K. U., Skapavets, K. Y., Akhremchuk, A. E., Kirsanava, N., Sidarenka, A. V., & Valentovich, L. N. (2022) · Experimental Biology and Biotechnology · doi:10.33581/2957-5060-2022-2-48-59
The microbiome and cancer immunotherapy
Niederhuber, J. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87763-3.00020-4
Chen, X., Wang, G.-J., Qin, L., Hu, B., & Li, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.28.542655
Liu, Y., Wu, B., Wang, Y., Bai, J., Wang, G., Zhao, S., Su, S., Lu, B., Hu, Y., Ouyang, W., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3841701/v1 · Cited by 1
Disputes and Challenges of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4910-0
Liu, Y., Wu, B., Wang, Y., Bai, J., Wang, G., Zhao, S., Lu, B., Hu, Y., Ouyang, W., Guo, Z., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4382702/v1
Association of BCMA-Targeted CAR-T Cell Therapy and the Gut Microbiome in Multiple MyelomaPreprint
Wang, X., Hu, X., Pan, M., Qian, C., Peng, L., Lü, J., Qiang, W., Jin, L., Hao, Y., Chao, Z., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5270396
Borgers, J. S. W., Burgers, F. H., Terveer, E. M., van Leerdam, M. E., Korse, C. M., Kessels, R., Flohil, C. C., Blank, C. U., Schumacher, T. N., van Dijk, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22603451
Introduction to gut microbiota in cancer metabolism
Anitha, K., Mishra, N., & Rath, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33459-7.00001-6
Hou, A. Y., Elantably, D., Manochakian, R., Velcheti, V., Li, S., Zhao, Y., & Lou, Y. (2026) · Cancers · doi:10.3390/cancers18081291
Precision nutrition in breast cancer: Towards patient- and tumour-informed dietary strategies
Crespo-Garcia, C., Taaffe, D. R., Peddle‐McIntyre, C. J., Jeffery, E., Campbell, J. P., Thomas, R., Galvao, D. A., & Newton, R. U. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106670
Enwere, M., Bryan, N. S., Onu, A., Neufeld, M., Hussein, M. T. E., Yakub, I., Omale, C., Onyedike, O., Atim, T., Agbeyomi, O. A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1904698
Gut microbiome in modulating immune checkpoint inhibitors
Bade, J. D., Shaik, A. R., Nelluri, K. D. D., Nelluri, S., & Alaparthi, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33206-7.00012-1
Metadata
- Authors
- Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K.
- Affiliations
- Tongji Hospital (CN)
- Corresponding author
- Chu, Qian
- Wu, Kongming
- Venue
- Journal of Hematology & Oncology
- Published
- 2018-03-27
- Volume
- 11
- Issue
- 1
- Pages
- 47-47
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC5870075
- OpenAlex
- W2794616539
- Cited by
- 179
- References
- 110
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 17 · 2023: 23 · 2022: 32 · 2021: 26 · 2020: 24 · 2019: 26 · 2018: 10
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81572608 and 81172422, 81672984)
- Wuhan Science and Technology Bureau (2017060201010170)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, immune checkpoint inhibitors, immunotherapy efficacy, cancer immunotherapy, treatment resistance, predictive biomarkers, commensal bacteria, anticancer mechanism, microbiome manipulation
- MeSH terms
- Gastrointestinal Microbiome, Humans, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
